Press Release4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 ...

ADCs are a rapidly growing drug therapy for solid tumors due to the cytotoxic effects of chemotherapeutic drugs combined with antibodies targeting tumor-associated antigens (TAAs). The ADCs mAb ...

In ADC therapy, payload delivery relies on a selective antibody binding event. Think of ADC therapy as less like a sledgehammer and more like a scalpel. Because antibodies are so large – around ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said ...

In addition, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services for a new ADC therapy. Based on an established relationship grounded in quality and delivery, the ...